Welcome to our dedicated page for Armata Pharmctcl SEC filings (Ticker: ARMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Armata Pharmaceuticals filings document a NYSE American-listed biotechnology issuer developing bacteriophage-based product candidates for bacterial infections. Current reports on Form 8-K record FDA Fast Track and Qualified Infectious Disease Product designations for AP-SA02, financial-results releases, corporate updates, board appointments, annual meeting matters, and amendments to existing credit agreements with Innoviva Strategic Opportunities.
Proxy and governance filings cover board composition, director compensation, executive compensation disclosures, shareholder voting matters, and the company's common stock structure. Material-event filings also describe financing arrangements, warrant-related amendments, and furnished press releases tied to the AP-SA02 and AP-PA02 clinical-development platform.
Armata Pharmaceuticals, Inc. is asking shareholders to vote at its June 11, 2026 annual meeting on four items: electing seven directors, approving executive pay on an advisory basis, choosing how often to hold future say‑on‑pay votes, and ratifying Ernst & Young as auditor for 2026.
Innoviva, Inc. beneficially owns 60,699,915 shares, or 83.9% of common stock outstanding as of April 17, 2026, giving it effective control. The proxy highlights Board independence, committee structures, and a separate independent Chair. It also notes Ernst & Young’s audit opinion for 2025 included substantial doubt about Armata’s ability to continue as a going concern due to recurring losses and negative operating cash flows.
For 2025, CEO Deborah Birx received total compensation of $1,249,889, Chief Business Officer Pierre Kyme received $791,575, and Principal Financial Officer David House received $554,770, combining salary, bonuses, equity awards and incentives. The Board recommends voting for all four proposals and an annual say‑on‑pay frequency.
Armata Pharmaceuticals, Inc. appointed Dr. Daniel B. Gilmer, 39, to its Board of Directors, effective April 24, 2026, to serve until the next annual shareholder meeting. He will receive the Company’s standard non-management director compensation, including a $40,000 annual cash retainer.
Dr. Gilmer is expected to receive a stock option to purchase 51,280 shares of common stock at the fair market value on the grant date, vesting in equal installments over three years under Armata’s 2016 Stock Incentive Plan. The Company also entered into a standard indemnity agreement with him and noted there are no related-party or Item 404(a) transactions.
Armata highlighted Dr. Gilmer’s extensive background at Pfizer, where he leads commercial quality across more than 50 U.S. brands and previously helped launch an FDA‑approved antiviral and diagnostics portfolio. His experience in antimicrobial resistance and bacteriophage therapeutics aligns with Armata’s late clinical-stage phage-based pipeline.
Armata Pharmaceuticals, Inc. has scheduled its 2026 annual meeting of stockholders for June 11, 2026 at 8:30 a.m. Pacific Time at its principal executive offices in Los Angeles, California. Stockholders of record at the close of business on April 17, 2026 will be entitled to receive notice and vote at the meeting.
The company has set 5:00 p.m. Pacific Time on April 12, 2026 as the deadline for receipt of stockholder proposals and director nominations submitted under Section 2.6 of its Amended and Restated Bylaws. Proposals and nominations must be delivered in writing to the Corporate Secretary at Armata’s principal executive offices and must comply with the advance notice provisions in the bylaws.
Armata Pharmaceuticals is a late clinical-stage biotech developing bacteriophage therapies for difficult bacterial infections. It has completed three Phase 2 trials, including AP-PA02 for chronic Pseudomonas lung disease and AP-SA02 for complicated Staphylococcus aureus bacteremia, both showing favorable safety and encouraging microbiologic or clinical responses.
AP-SA02 received Qualified Infectious Disease Product designation and FDA End-of-Phase 2 feedback supporting a Phase 3 superiority trial expected to start in the second half of 2026. The company is also advancing preclinical AP-PA03 for ventilator-associated pneumonia and exploring additional S. aureus indications.
Armata relies heavily on funding from Innoviva affiliates, with multiple high-interest credit facilities, a $30 million convertible loan, and an at-the-market equity program of up to $100 million. As of June 2025, non-affiliate equity was valued at about $21.1 million, with 36,632,775 shares outstanding as of March 18, 2026.
Armata Pharmaceuticals reported a sharp deterioration in results for the quarter and year ended December 31, 2025. Fourth-quarter grant revenue was $1.1 million, while research and development expenses fell to $6.1 million and general and administrative expenses were $3.4 million. The company recorded a $5.4 million impairment on vacated office and R&D space, contributing to a fourth-quarter operating loss of $13.8 million.
For full-year 2025, Armata posted a net loss of $173.8 million, compared with a $18.9 million net loss in 2024, driven largely by a $121.0 million non-cash loss from changes in fair value of a convertible loan and higher interest expense. Total liabilities rose to $295.5 million, resulting in a stockholders’ deficit of $218.6 million. Cash, cash equivalents and restricted cash were $14.1 million at year-end. In January 2026, Armata extended the maturity of multiple credit agreements to June 1, 2027 and lengthened warrant expirations. Its audited 2025 financial statements include an explanatory going concern paragraph. As of March 18, 2026, Armata had 36.6 million common shares outstanding.
Armata Pharmaceuticals reported that it will delay announcing its fourth quarter and full-year 2025 financial results, while still expecting to file its Form 10-K on or before March 31, 2026. At the same time, the company highlighted an End-of-Phase 2 meeting with the FDA that aligned on a development plan for AP-SA02 in complicated Staphylococcus aureus bacteremia.
Armata plans to initiate a rigorously designed Phase 3 superiority study of AP-SA02 later in 2026 and has received Qualified Infectious Disease Product (QIDP) designation from the FDA for this program. The company also acknowledged ongoing support from Innoviva and the U.S. Department of Defense for its bacteriophage therapy pipeline.
Armata Pharmaceuticals, Inc. Chief Business Officer Pierre Kyme reported a small tax-related share disposition on common stock. On March 14, 2026, 1,030 shares were withheld at $10.54 per share to satisfy income tax and withholding obligations tied to restricted stock unit settlement. Following this transaction, Kyme directly holds 9,461 common shares.
Armata Pharmaceuticals’ CEO Deborah Birx reported a routine tax-withholding transaction involving company stock. On this Form 4, 4,919 shares of common stock were withheld by the company at $10.54 per share to cover income-tax obligations tied to the net settlement of restricted stock units. This was a tax-withholding disposition, not an open-market sale, and left Birx with direct ownership of 212,458 common shares.
Armata Pharmaceuticals director Robin Kramer received a grant of stock options, giving the right to buy 25,640 shares of common stock at an exercise price of $11.61 per share. These options vest in full on March 9, 2027, subject to continuous service, and expire on March 9, 2036. Following this grant, Kramer holds 25,640 stock options directly.
Armata Pharmaceuticals’ Chief Business Officer receives new stock option grant. On March 9, 2026, Pierre Kyme was granted stock options covering 183,142 shares of Armata Pharmaceuticals common stock at an exercise price of $11.6100 per share, expiring on March 9, 2036.
These options were awarded as a compensation grant and are held directly. According to the terms, 25% of the options vest on March 9 of each of 2027, 2028, 2029, and 2030, assuming continuous service through each vesting date. No open‑market purchases or sales were reported in this filing.